Suspected PE at 15 Weeks' Gestation
A 31-year-old woman at 15 weeks' gestation presents with two days of pleuritic chest pain and dyspnea. Heart rate 108, BP 118/74, SpO2 96% on room air, no hypotension. The right calf is swollen and tender and the D-dimer is 1,900 ng/mL. The chest radiograph is normal. Creatinine 0.8 mg/dL, no iodinated contrast allergy, no asthma. Low-molecular-weight heparin was started in the emergency department. The referring team wants to "rule out PE tonight" with whatever study gives the least radiation to the fetus. Your department has SPECT/CT, a Technegas generator and DTPA aerosol; the standard adult perfusion dose is 4.0 mCi (148 MBq) 99mTc-MAA, and your protocol permits a reduced-activity perfusion-only study.
1. Which imaging pathway do you recommend, and how do you justify it when the emergency physician frames the choice purely as fetal dose?
Read the worked answer
Recommend a ventilation/perfusion study (SPECT where available), starting with perfusion, rather than CTPA. The clinical facts drive this: pleuritic pain, unilateral leg swelling, tachycardia and a high D-dimer with a normal chest radiograph.
Reasoning to give the referring team:
- The "fetal dose" framing is the wrong axis. Both CTPA and perfusion imaging deliver fetal doses in the same low range (well under 1 mGy, orders of magnitude below any deterministic threshold). The real difference is maternal breast dose, which is roughly an order of magnitude lower with perfusion-only imaging than with CTPA.
- A normal chest radiograph maximizes V/Q specificity. Ventilation/perfusion interpretation degrades when there is parenchymal opacity, so the normal film is a point in favor of V/Q, not a neutral detail.
- The patient is hemodynamically stable, so there is time for a good study; anticoagulation should not be withheld while waiting.
- Define the exit strategy up front: if the study is non-diagnostic in a patient with high pre-test probability, the next step is CTPA (or treat empirically), agreed with the emergency physician before the patient is injected.
2. Write the technical protocol you would actually run in the department (activity, acquisition, ventilation add-on, communication).
Read the worked answer
Protocol
- Perfusion first, at reduced activity: 37–74 MBq (1–2 mCi) 99mTc-MAA, i.e., one-quarter to one-half the 4 mCi adult dose. Enough counts for interpretation, minimal fetal and maternal dose.
- Technique: supine, patient voided beforehand, 500–750 k counts per view plus SPECT if available; record the actual activity and time.
- Ventilation only if needed: if perfusion is indeterminate, add Technegas or DTPA aerosol at low activity. Do not add ventilation reflexively if perfusion alone answers the question - each step costs dose and time.
- Avoid repeated MAA boluses. Each additional injection adds dose without adding information; trouble-shoot poor delivery before re-injecting.
- Communication: document gestational age on the request, discuss with the nuclear medicine physician and, if there is any question, the obstetric team; note that MAA is not contraindicated in pregnancy and that particle numbers are small.
- Interpret with explicit criteria and record a probability category, not a free-text impression, so the team knows what to do with a non-diagnostic result.
3. The radiologist re-reads the chest film and reports a wedge-shaped opacity at the right base. How does that change your plan, and why?
Read the worked answer
Switch to CTPA.
- With basilar airspace disease, a perfusion defect at the same site is a matched defect and carries no diagnostic weight. The study is likely to come back indeterminate - the worst outcome in a patient who needs an answer tonight.
- CTPA visualizes thrombus directly, is unaffected by the parenchymal opacity, and may identify an alternative diagnosis (pneumonia, infarction, effusion) that explains the presentation.
- The radiation argument does not reverse: fetal dose from CTPA remains very low, and the maternal breast dose difference no longer outweighs a study that will probably be non-diagnostic.
- Do not apply abdominal shielding for CTPA; it does not reduce fetal dose meaningfully and can degrade the acquisition.
- Keep the pre-test probability in view: a very high probability patient may warrant empiric anticoagulation while imaging is arranged, regardless of which test is chosen.